107 related articles for article (PubMed ID: 29600365)
1. Predictive Marker: HER2 in Esophageal Adenocarcinoma.
Subasinghe D; Acott N; Kumarasinghe MP
Methods Mol Biol; 2018; 1756():119-134. PubMed ID: 29600365
[TBL] [Abstract][Full Text] [Related]
2. Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus.
Ilson DH; van Hillegersberg R
Gastroenterology; 2018 Jan; 154(2):437-451. PubMed ID: 29037469
[TBL] [Abstract][Full Text] [Related]
3. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
5. Human epidermal growth factor receptor 2 overexpression and amplification in endoscopic biopsies and resection specimens in esophageal and junctional adenocarcinoma.
van Hagen P; Biermann K; Boers JE; Stoss O; Sleddens HF; van Lanschot JJ; Dinjens WN; Rueschoff J; Wijnhoven BP
Dis Esophagus; 2015; 28(4):380-5. PubMed ID: 24611982
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach.
Villanacci V; Rossi E; Grisanti S; Bassotti G; Ferrari VD; Missale G; Minelli L; Cengia P; Marini G; Cestari R
Minerva Gastroenterol Dietol; 2008 Dec; 54(4):347-53. PubMed ID: 19047975
[TBL] [Abstract][Full Text] [Related]
7. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
[TBL] [Abstract][Full Text] [Related]
9. Are biopsy specimens predictive of HER2 status in gastric cancer patients?
Pirrelli M; Caruso ML; Di Maggio M; Armentano R; Valentini AM
Dig Dis Sci; 2013 Feb; 58(2):397-404. PubMed ID: 22918687
[TBL] [Abstract][Full Text] [Related]
10. Early HER2 dysregulation in gastric and oesophageal carcinogenesis.
Fassan M; Mastracci L; Grillo F; Zagonel V; Bruno S; Battaglia G; Pitto F; Nitti D; Celiento T; Zaninotto G; Fiocca R; Rugge M
Histopathology; 2012 Nov; 61(5):769-76. PubMed ID: 22882541
[TBL] [Abstract][Full Text] [Related]
11. Progress and challenges in HER2-positive gastroesophageal adenocarcinoma.
Zhao D; Klempner SJ; Chao J
J Hematol Oncol; 2019 May; 12(1):50. PubMed ID: 31101074
[TBL] [Abstract][Full Text] [Related]
12. Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival.
Thompson SK; Sullivan TR; Davies R; Ruszkiewicz AR
Ann Surg Oncol; 2011 Jul; 18(7):2010-7. PubMed ID: 21267790
[TBL] [Abstract][Full Text] [Related]
13. Target Therapy for Esophageal Adenocarcinoma.
Lam KO; Kwong DLW
Methods Mol Biol; 2018; 1756():51-65. PubMed ID: 29600359
[TBL] [Abstract][Full Text] [Related]
14. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
[TBL] [Abstract][Full Text] [Related]
15. Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status.
Wang T; Hsieh ET; Henry P; Hanna W; Streutker CJ; Grin A
Hum Pathol; 2014 May; 45(5):970-5. PubMed ID: 24656529
[TBL] [Abstract][Full Text] [Related]
16. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
[TBL] [Abstract][Full Text] [Related]
17. HER2 assessment by silver in situ hybridization: where are we now?
Sanguedolce F; Bufo P
Expert Rev Mol Diagn; 2015 Mar; 15(3):385-98. PubMed ID: 25578771
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.
Wang YK; Chen Z; Yun T; Li CY; Jiang B; Lv XX; Chu GH; Wang SN; Yan H; Shi LF
World J Gastroenterol; 2015 Apr; 21(15):4680-7. PubMed ID: 25914479
[TBL] [Abstract][Full Text] [Related]
19. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
20. Introduction: Esophageal Adenocarcinoma: Updates of Current Status.
Lam AK
Methods Mol Biol; 2018; 1756():1-6. PubMed ID: 29600355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
